Closed Protocol
Resources for Members
Clinical Trials
Files with the extension 'zip' require the Winzip application to open.
05-295
CALGB 50303: PHASE III RANDOMIZED STUDY OF R-CHOP V. DOSE-ADJUSTED EPOCH-R WITH MOLECULAR PROFILING IN UNTREATED DE NOVO DIFFUSE LARGE B-CELL LYMPHOMAS more details
Protocol
Consent Form
|
|
| |
06-155
CALGB 50401: A RANDOMIZED PHASE II TRIAL OF LENALIDOMIDE VS. RITUXIMAB + LENALIDOMIDE IN RECURRENT FOLLICULAR NON-HODGKIN LYMPHOMA(NHL) AFTER RELAPSE FROM A RITUXIMAB-CONTAINING COMBINATION REGIMEN more details
Protocol
Consent Form
|
|
| |
07-017
A PHASE II, MULTICENTER, OPEN-LABEL TRIAL EVALUATING THE ACTIVITY AND TOLERABILITY OF ROMIDEPSIN (DEPSIPEPTIDE, FK228) IN PROGRESSIVE OR RELAPSED PERIPHERAL T-CELL LYMPHOMA FOLLOWING PRIOR SYSTEMIC THERAPY more details
Protocol
Consent Form
|
|
| |
2007-410
A Randomized Phase IIB Placebo-Controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-Line Treatment of Patients more details
Protocol
Consent Form
|
|
| |
2008-186
Phase I Clinical Trial of Bendamustine, Lenalidomide and Rituximab in B-cell
Lymphoid Malignancies more details
Protocol
Consent Form
|
|
| |
2008-014
CALGB 50501: A PHASE II TRIAL OF BORTEZOMOB + LENALIDOMIDE FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA more details
Protocol
Consent Form
|
|
| |
2008-311
CALGB 50602: A Phase II Study of Galiximab (Anti-CD80) for Patients with Relapsed/Refractory Hodgkin Lymphoma more details
Protocol
Consent Form
|
|
| |
2008-582
A Phase II Trial of Doxil, Rituximab, Cyclophosphamide, Vincristine and Prednisone (DR-COP) in Patinents with Newly Diagnosed AIDS-Associated B-Cell Non-Hodgkins Lymphoma more details
Protocol
Consent Form
|
|
| |
2009-211
An Open-Label, Dose-Escalation, Phase I Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients with Lymphoma more details
Protocol
Consent Form
|
|
| |
2009-316
MI-CP204: Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Agaisnt CD19, in Adult Subjects with Relapsed or Refractory Advanced B-Cell Malignancies more details
Protocol
Consent Form
|
|
| |
|